RESKO: Repositioning drugs by using side effects and knowledge from ontologies
- Submitting institution
-
University of Sunderland
- Unit of assessment
- 11 - Computer Science and Informatics
- Output identifier
- 673
- Type
- D - Journal article
- DOI
-
10.1016/j.knosys.2018.06.017
- Title of journal
- Knowledge-Based Systems
- Article number
- -
- First page
- 34
- Volume
- 160
- Issue
- -
- ISSN
- 0950-7051
- Open access status
- Compliant
- Month of publication
- November
- Year of publication
- 2018
- URL
-
http://sure.sunderland.ac.uk/id/eprint/9701/
- Supplementary information
-
-
- Request cross-referral to
- 3 - Allied Health Professions, Dentistry, Nursing and Pharmacy
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
3
- Research group(s)
-
-
- Citation count
- 3
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- RESKO has attracted interest for drug development in industry (Sterling Pharmaceuticals). We investigate how drugs developed initially for one disease may be repurposed for another, based on similar side-effects. Similarity of unwanted side-effect suggests the same biochemical pathways are targeted by the new drug. Not all patients will have side-effects and therefore the drug may be of benefit. We examine a difficult disease, Alzheimer’s and have validated our approach by looking at a range of clinical trials. Sterling Pharmaceuticals is keen to use RESKO for other diseases to reduce the number of drug withdrawals in Phase III (Abdul Rehman, abdul@sterlingpharma.co.uk).
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -